← brief for 2026-08-10 · Slowing decline

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

Trial No results yet Not peer reviewed

Key takeaways

This small study measures how a drug called eloralintide moves through the body in people with reduced kidney function, compared with healthy people. It runs about 14 weeks per person and helps set safe dosing. It is an early pharmacology study with no health results yet.

Who did this work

Run by Eli Lilly and Company. Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (Eli Lilly and Company)
Sites: Floridian Clinical Research, LLC · Omega Research Orlando LLC

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-06
https://clinicaltrials.gov/study/NCT07426380